Association of Hepatitis B Virus Infection With Other Sexually Transmitted Infections in Homosexual Men

Robert S. Remis, MD, MPH, FRCP(c), Annie Dufour, PhD, MSc, Michel Alary, MD, PhD, Jean Vincelette, MD, FRCP(c), Joanne Otis, PhD, Benoît Massé, PhD, Bruno Turmel, MD, Roger LeClerc, BA, Raymond Parent, MSc, René Lavoie, BA, and the Omega Study Group

Homosexual men in Montreal, Quebec, have been seriously affected by the HIV epidemic. Of the 4204 AIDS cases in Montreal reported up to June 1999, 2924 (70%) were among men who have sex with men (MSM). In 1996, we began the Omega cohort to estimate HIV incidence among Montreal MSM, to identify risk factors associated with HIV seroconversion, and to characterize sexual behavior and its evolution.

MSM are also at risk for hepatitis B virus (HBV) infection, which is largely related to the same sexual behaviors as is HIV infection. Hepatitis B infection is serious; 5% to 10% of infected adults remain chronic carriers, usually for life, and a significant minority progress to chronic active hepatitis, cirrhosis, hepatic insufficiency, and hepatocellular carcinoma. Although an effective and safe vaccine was licensed in 1982, not all homosexual men have been vaccinated, owing to limited knowledge about HBV infection and vaccine, low perceived susceptibility, high cost, and myths about its adverse effects.

Given the opportunity afforded by the Omega study, we chose to study the epidemiologic characteristics of HBV infection among MSM in Montreal. Therefore, we included questions concerning history of symptoms possibly related to viral hepatitis, vaccination status, and previous diagnostic testing for HBV infection, in addition to the many questions related to demography and sexual behavior included in the HIV study.

Methods

Subject Recruitment

The Omega study recruits HIV-seronegative homosexual men at clinical and community settings; we promoted the study at the offices of physicians with large gay practices, at gay bars and bathhouses, at Gay Pride Day, through community organizations, and via advertisements and articles in the Montreal gay press. Subjects were men who had had sex with another man in the previous year. (We use the terms MSM and homosexual men interchangeably in the present report to reflect this behavioral definition.) Enrollment began in October 1996. We oversampled younger men to obtain at least 50% of subjects younger than 30 years. Participants were followed up every 6 months. At each visit, a questionnaire was administered; the questionnaire included interviewer-administered and self-administered questions. The latter focused on sexual practices and constituted about 40% of the questionnaire (the questionnaire is available on request). At each visit, we tested for HIV and syphilis serologic markers; participants who tested positive for HIV on their first visit were excluded from further study.

Robert S. Remis is with the Department of Public Health Sciences, University of Toronto, Toronto, Ontario. Robert S. Remis and Bruno Turmel are with the Département de santé publique, Montréal-Centre, Montreal, Quebec. Annie Dufour, Michel Alary, and Benoît Massé are with the Groupe de recherche en épidémiologie, Centre hospitalier affilié universitaire, Hôpital du Saint-Sacrement, Quebec, Quebec. Jean Vincelette is with the Centre hospitalier de l’Université de Montréal, Campus Saint Luc, Montreal, Quebec. Joanne Otis is with the Département de sexologie, Université du Québec à Montréal, Montreal, Quebec. Roger LeClerc is with COCQ-sida, Montreal, Quebec. Raymond Parent is with the Centre de santé publique de Québec, Quebec. René Lavoie is with Sérozéro, Montreal, Quebec.

Requests for reprints should be sent to Robert S. Remis, MD, MPH, FRCP(c), Department of Public Health Sciences, University of Toronto, McMurray Bldg, 4th Floor, 12 Queen’s Park Crescent West, Toronto, Ontario, Canada M5S 1A8 (e-mail: rs.remis@utoronto.ca).

This article was accepted February 17, 2000.
To learn about HBV infection among MSM in Montreal, we tested participants for HBV markers at their first visit. Unvaccinated participants without serologic evidence of previous HBV infection were offered vaccination at no charge, and persons who tested positive for hepatitis B surface antigen (HBsAg) were referred for medical evaluation. The questionnaire included questions related to hepatitis B, including vaccination, a history of jaundice, and knowledge of past hepatitis B infection. It also included questions that elicited detailed information about sexual behaviors, which were examined for possible correlation with HBV markers. In our study, we defined types of sexual partners for subjects as follows: “a regular partner is someone with whom you had sex at least twice, whom you intended to see and did see again, someone with whom you had a certain relationship (emotional, sexual, or otherwise),” and “a casual partner is someone with whom you had sex only once (a ‘one-night stand’), someone you did not intend to see again.”

Laboratory Analysis

We tested subjects for HIV and for syphilis (by rapid plasma reagin (NCS Diagnostics, Mississauga, Ontario) at each visit. Specimens positive by rapid plasma reagin were confirmed at the Laboratoire de santé publique du Québec by the micro-hemagglutination assay for antibodies to Treponema pallidum (MHA-TP; Fujirebio, Tokyo, Japan). We also tested sera of the first 500 subjects by enzyme immunoassay for antibody to hepatitis B core antigen (anti-HBc), antibody to hepatitis B surface antigen (anti-HBs), and HBsAg (Cobas Core System, Roche Diagnostics, Mississauga, Ontario). Subsequently, we tested subjects for anti-HBc and, if the results were positive, for anti-HBs and HBsAg.

We were concerned that self-reported histories of sexually transmitted disease (STD) might not be accurate, especially if infections occurred remotely (syphilis has not been frequent in this population for over 15 years). Therefore, to independently validate syphilis histories, we performed serologic testing for syphilis with the toluidine red unheated serum test (TRUST) and MHA-TP sera from men who reported having had syphilis and from a 1-in-5 random sample of unvaccinated men who did not. If one of the tests was positive or equivocal, sera were tested by fluorescent treponemal antibody absorption test (FTA-ABS-DS; Zeus Scientific, Inc, Raritan, NJ). MHA-TP and FTA-ABS-DS were performed at the Laboratoire de santé publique du Québec.

Statistical Analysis

We first carried out descriptive analyses of hepatitis B vaccination coverage and hepatitis B markers among subjects at their first visit. Next, we examined only those men who reported not having been vaccinated against hepatitis B and analyzed the demographic and sexual behavioral variables for possible correlations with HBV infection, including the number of sexual partners, sexual practices, and history of STDs. We considered the presence of any HBV marker as indicative of past or present HBV infection. For the univariate analysis, we tested for significance with the Fisher exact test and the \( \chi^2 \) test, using a threshold \( P \) value of .05. We examined variables associated with HBV in the univariate analysis and those identified in published studies in a multivariate logistic regression model with SAS, version 6.11 (SAS Institute, Cary, NC). We also retained in the model possible confounders if their inclusion changed the odds ratio of other variables by 10% or more.

Results

From October 17, 1996, to July 31, 1997, 653 HIV-seronegative men were recruited. Age ranged from 18 to 73 years, with a mean of 34.5 years and a median of 33 years; 39% were younger than 30 years (the age distribution of subjects reflects in part the oversampling of younger MSM). Subjects were predominantly francophone (71%), born in Canada (78%), and resident in Montreal (90%). Although most (74%) had college or higher education, annual income was relatively low (47% below Can $20000).

Of the 625 men indicating hepatitis B vaccination status, 297 (48%) reported having received at least 1 dose. Overall, 175 study subjects (28%) completed the 3-dose course, 78 (13%) had 2 doses, and 41 (6.6%) received 1 dose. Forty-three percent of subjects had been previously tested for HBV markers, although the date of testing was not known.

Of the 328 men with known HBV marker status who reported not having been vaccinated, 14 (4.3%) were HBsAg positive, 101 (30.8%) had anti-HBs, 7 (2.1%) had anti-HBc alone, and 12 (3.7%) had anti-HBc alone. Thus, 134 (41%) had an HBV marker and 127 (39%) had either HBsAg or anti-HBc. Of the 297 men who reported having been vaccinated, 1 (0.3%) was HBsAg positive and 40 (14%) had either HBsAg or anti-HBc; it is not known whether the HBV infection occurred before or after vaccination.

With respect to syphilis serology, 11 (41%) of the 27 men who reported having had syphilis tested positive by the FTA-ABS-DS or MHA-TP, compared with none of the 56 randomly selected unvaccinated men who had not reported such history (\( P=0.00001, \) Fisher exact test).

The rest of the results focus on HBV markers among the 328 participants who reported not having been vaccinated. A subject was considered to have had past or to have present HBV infection if we detected anti-HBc, anti-HBs, or HBsAg. As noted above, among unvaccinated men, 41% had at least 1 HBV marker.

Among the sociodemographic variables examined (Table 1), HBV infection prevalence was associated with age, varying from 9.8% among those younger than 25 years to 61% among those 35 years or older. HBV marker prevalence was almost twice as high among Montreal residents compared with subjects residing outside Montreal. The univariate results for selected behavioral variables are shown in Table 2. We observed a strong correlation between HBV infection and increasing number of sexual partners: HBV prevalence increased from 6.3% among men with fewer than 6 lifetime sexual partners to 70% among those with 100 or more such partners. The prevalence of HBV markers among men who had received money for sex was almost twice that of men who had not. The consumption of alcohol before sex and the use of drugs before sex were both associated with HBV marker prevalence.

Of the 328 subjects, 297 (91%) responded to all 6 questions about a lifetime history of specific STDs; 131 subjects reported having at least 1 STD, and 31 subjects reported a genito-urecral STD. We observed a strong correlation of HBV markers with each of the STDs examined (Table 3); among those with a history of each STD, HBV prevalence was about twice as high as among those without such a history. In the multivariate logistic regression analysis including variables significant in the univariate analysis (Table 4), the following 7 variables were independently associated with HBV infection: history of ulcerative STD (herpes, syphilis, or genital ulcer unspecified), injection drug use, history of gonorrhea or chlamydia, having had a partner with HIV or AIDS, 50 or more casual sex partners, received money for sex, and 20 or more regular sex partners. For unprotected anal sex with a casual sex partner, the association was borderline significant. For genito-urecral infections, the odds ratio was 10.1 (95% confidence interval=2.60, 53.9).

Discussion

We found that a substantial proportion of MSM in Montreal appear to have been exposed to HBV infection but that fewer than half have been vaccinated. HBV infection was frequent among unvaccinated men: 41% had been infected and 4.3% were chronic carriers, a con-
We also observed that in this population, hepatitis B infection was associated with most sexual behavior variables examined and, in particular, was strongly and independently associated with a history of STD, especially genito- ulcerative infections.

There are several limitations to our study. First, subjects were not randomly selected; they volunteered for the study and may not be representative of MSM in Montreal generally. Second, we obtained data on behaviors, sociodemographic status, STD history, and hepatitis B vaccination from a questionnaire. Except in the case of syphilis, we did not independently validate the information obtained, although we have no reason to believe that there was any systematic bias in this regard. We examined lifetime experiences reported at the time of the first visit for possible associations with HBV marker prevalence. In this design, we could not determine whether the reported STD predated the HBV infection. Also, a history of STD may be a correlate of some other high-risk sexual exposure that is responsible for the increased risk of HBV infection, in which case our observed associations of HBV infection with STDs would be spurious. Nevertheless, we adjusted for many variables related to sexual behaviors, and the strong associations remained.

Among unvaccinated subjects, 7 men (2.1%) had anti-HBs but no anti-HBc antibody. These subjects may have been vaccinated but failed to report it, or they may have been infected and lost anti-HBc antibody. In our analysis, we assumed the latter. If some subjects had been vaccinated, this would have introduced misclassification error; however, the impact of such an error would be negligible and, in any case, would have decreased our power to detect differences.

We found an overall prevalence of HBV markers of 48% among men in the Omega cohort. It is difficult to compare HBV marker prevalence among different homosexual populations, since prevalence varies with age, vaccination status, and calendar time, among other variables. The prevalence of anti-HBc or HBsAg (markers of past HBV infection) among unvaccinated men was 39%, compared with 14% among those apparently vaccinated (anti-HBs alone was excluded, since it probably indicates a previous vaccination). The latter figure does not necessarily reflect vaccine failure, since HBV infection may have occurred before vaccination.

To the best of our knowledge, no other data on HBV markers from other studies of MSM in Montreal are available for comparison. A study of 150 homosexual STD clinic patients in Edmonton, Alberta, in 1982 showed an HBV marker prevalence of 39%. One might expect a higher prevalence among STD clinic attendees, but it is difficult to compare Montreal and Edmonton, which is a smaller, more

ting with serious long-term consequences.
isolated city. In a more comparable population of MSM in Vancouver recruited from general medical practices in 1982 through 1984, HBV marker prevalence was 68%. It is likely that, owing to the dramatic decreases in risky sexual behavior among MSM in response to the HIV epidemic, hepatitis B infection among Montreal MSM is less than it was previously.

More recent studies have been carried out elsewhere. Among 306 unvaccinated homosexual men attending a genitourinary clinic in London, England, in 1990, anti-HBc prevalence was 50%. A study of 417 unvaccinated HIV-negative MSM in Seattle in 1995 showed an HBV marker prevalence of 35%. This was somewhat lower than the HBV prevalence of 48% we observed despite very similar study populations with respect to demographic characteristics, STD histories, and HIV status.

The role of other STDs, especially genitoulcerative infections, in HBV infection is of interest. Previous studies have examined possible risk factors for HBV infection in both heterosexual and homosexual populations. Since associations observed in such studies may be markers for other associations, studies that collected demographic and risk-related data (e.g., on sexual practices and past STDs) and used multivariate analysis to adjust for possible confounding are of particular interest. Both the duration of homosexual activity and the number of male sexual partners were independently associated with HBV infection in studies carried out in Canada, the United States, and Europe. Receptive anal intercourse was identified in at least 3 studies and insertive anal intercourse in 1 study. This is analogous to HIV infection (these 4 studies examined behaviors that occurred before the HIV epidemic, when condom use among MSM was not frequent).

The independent association of HBV infection with STD has been observed previously in heterosexual and homosexual populations. In a study of 1062 homosexual men in Baltimore in 1984, both a history of gonorrhea and a history of any STD were associated with HBV markers among at least 3 of the 5 subgroup analyses presented, with odds ratios in the range of 2.5 to 4.6 and 1.4 to 1.7, respectively. Willoughby and colleagues, studying 576 MSM recruited from medical practices in Vancouver, found that a self-reported history of syphilis was associated with the presence of HBV markers, with an adjusted odds ratio of 2.9. A study of HBV infection among 317 MSM attending colleges in Boston observed a statistically significant association with a history of STD, with an adjusted odds ratio of 3.1. Finally, Stroffolini and colleagues studied 252 homosexual men attending an STD clinic in Rome, Italy, and, in a multivariate model, found an association with positive syphilis serology (odds ratio=1.9).

In our study, we were unable to independently validate the self-reported episodes of clinical syphilis; a history of syphilis may be a marker for a sexual practice not captured in our study, and the observed association with HBV infection may be artifactual. This, however, is unlikely. A similar association has been observed in studies in which active syphilis was diagnosed directly at the time of the study. Second, our subjects were well educated and would likely have excellent knowledge of STD. A diagnosis of syphilis is specific, and we asked about this by using the exact term in French. Finally, we observed a strong association between the presence of antibody and a self-reported history of syphilis. Although we detected treponemal antibody in only 41% of the 27 men with a history of syphilis, this is not surprising, since antibodies do not persist indefinitely in all patients.

Only about half of our subjects reported having received hepatitis B vaccine, a vaccine that is safe and effective. MSM are at high risk for hepatitis B, and vaccination for this group was recommended almost 10 years ago. Clearly, new strategies are needed to improve vaccine coverage. For this reason, we have analyzed our data specifically to identify factors associated with failure to initiate and complete HBV vaccination.

Our finding of a strong association of HBV infection with STD reinforces the importance of timely diagnosis and treatment of STDs and, in particular, genitoulcerative infections. This will also help to prevent HIV infection. Persons diagnosed with an STD must also be offered hepatitis B vaccination.

The table below presents the results of a multivariate logistic regression model examining associations of sociodemographic, sexual behavioral, and sexually transmitted disease (STD) history variables with hepatitis B virus markers among unvaccinated study participants at first visit.

### TABLE 3: Association of History of Sexually Transmitted Diseases and Hepatitis B Virus Infection Among Unvaccinated Participants at First Visit (n=328): Montreal, 1996–1997

<table>
<thead>
<tr>
<th>History of—</th>
<th>n</th>
<th>Infected, %</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gonorrhea</td>
<td>No</td>
<td>230</td>
<td>29</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>81</td>
<td>74</td>
</tr>
<tr>
<td>Chlamydia</td>
<td>No</td>
<td>287</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>21</td>
<td>71</td>
</tr>
<tr>
<td>Syphilis</td>
<td>No</td>
<td>303</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>14</td>
<td>93</td>
</tr>
<tr>
<td>Herpes</td>
<td>No</td>
<td>301</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>17</td>
<td>88</td>
</tr>
<tr>
<td>Condylomata</td>
<td>No</td>
<td>259</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>57</td>
<td>60</td>
</tr>
<tr>
<td>Genital ulcer, unspecified</td>
<td>No</td>
<td>309</td>
<td>40</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>5</td>
<td>80</td>
</tr>
</tbody>
</table>

*Note. CI=confidence interval.*

### TABLE 4: Results of Multivariate Logistic Regression Model Examining Associations of Sociodemographic, Sexual Behavioral, and Sexually Transmitted Disease (STD) History Variables With Hepatitis B Virus Markers Among Unvaccinated Study Participants at First Visit (n=328): Montreal, 1996–1997

<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of ulcerative STD (herpes, syphilis, or genital ulcer)</td>
<td>10.1</td>
<td>2.60, 53.9</td>
</tr>
<tr>
<td>Injection drug use</td>
<td>5.16</td>
<td>1.20, 26.3</td>
</tr>
<tr>
<td>History of gonorrhea or chlamydia</td>
<td>4.04</td>
<td>1.88, 8.92</td>
</tr>
<tr>
<td>Sexual partner with HIV or AIDS</td>
<td>3.56</td>
<td>1.81, 7.13</td>
</tr>
<tr>
<td>≥50 casual partners during lifetime</td>
<td>3.35</td>
<td>1.60, 7.10</td>
</tr>
<tr>
<td>Received money for sex</td>
<td>3.01</td>
<td>1.21, 7.75</td>
</tr>
<tr>
<td>≥20 regular partners during lifetime</td>
<td>2.49</td>
<td>1.05, 6.09</td>
</tr>
<tr>
<td>Unprotected anal sex with casual partner</td>
<td>1.96</td>
<td>0.98, 3.93</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>1.02</td>
<td>0.988, 1.06</td>
</tr>
<tr>
<td>Alcohol and drugs before sex</td>
<td>0.562</td>
<td>0.260, 1.17</td>
</tr>
</tbody>
</table>

*Note. CI=confidence interval.*
Acknowledgments

The National Health Research and Development Program provided core funding for the study (grant R6605-4639-AIDS), and the Centre québécois de coordination sur le sida and the Fonds de la recherche en santé du Quebec (FRSQ) provided additional support. M. Alary is a research scholar of the FRSQ (grant 970097).

We wish to thank the physicians who helped to recruit study participants, the gay and HIV-related community organizations that collaborated closely with us, and the Montreal Regional Public Health Department, which provided hepatitis B vaccine at no cost. We are also indebted to the dedicated employees of the Omega study for recruiting subjects and collecting data and the technical staff, Serology Laboratory, Centre hospitalier de l’Université de Montréal, Campus Saint-Luc, who performed the laboratory tests. Above all, we wish to thank the men who contributed to the study protocol and provided statistical advice. B. Turnel, coinvestigator, helped in the conception and implementation of the study and ensured liaison with the Montreal Public Health Department. R. LeClerc and R. Lavoie, coinvestigators, helped in the conception and implementation and developed the community component of the study. R. Parent, coinvestigator, helped in the conception and implementation of the study. All coauthors reviewed and approved the manuscript.

References